Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

TGFβ Programs Central Memory Differentiation in Ex Vivo-Stimulated Human T Cells.

Dahmani A, Janelle V, Carli C, Richaud M, Lamarche C, Khalili M, Goupil M, Bezverbnaya K, Bramson JL, Delisle JS.

Cancer Immunol Res. 2019 Sep;7(9):1426-1439. doi: 10.1158/2326-6066.CIR-18-0691. Epub 2019 Jul 15.

PMID:
31308016
2.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA.

Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019.

3.

Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Walsh SR, Bastin D, Chen L, Nguyen A, Storbeck CJ, Lefebvre C, Stojdl D, Bramson JL, Bell JC, Wan Y.

J Clin Invest. 2019 Feb 1;129(2):518-530. doi: 10.1172/JCI121004. Epub 2018 Dec 18.

4.

The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity.

Helsen CW, Hammill JA, Lau VWC, Mwawasi KA, Afsahi A, Bezverbnaya K, Newhook L, Hayes DL, Aarts C, Bojovic B, Denisova GF, Kwiecien JM, Brain I, Derocher H, Milne K, Nelson BH, Bramson JL.

Nat Commun. 2018 Aug 3;9(1):3049. doi: 10.1038/s41467-018-05395-y.

5.

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, Pol J, Bramson JL, Wan Y.

Cell Rep. 2018 Jul 17;24(3):642-654. doi: 10.1016/j.celrep.2018.06.040.

6.

Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model.

Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA.

Cancer Immunol Res. 2018 Oct;6(10):1174-1185. doi: 10.1158/2326-6066.CIR-18-0144. Epub 2018 Jul 17.

PMID:
30018043
7.

Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.

Verschoor CP, Lelic A, Parsons R, Evelegh C, Bramson JL, Johnstone J, Loeb MB, Bowdish DME.

J Infect Dis. 2017 Jul 15;216(2):191-197. doi: 10.1093/infdis/jix257.

8.

AMPK β1 reduces tumor progression and improves survival in p53 null mice.

Houde VP, Donzelli S, Sacconi A, Galic S, Hammill JA, Bramson JL, Foster RA, Tsakiridis T, Kemp BE, Grasso G, Blandino G, Muti P, Steinberg GR.

Mol Oncol. 2017 Sep;11(9):1143-1155. doi: 10.1002/1878-0261.12079. Epub 2017 Jun 28.

9.

Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells.

Bassey-Archibong BI, Rayner LG, Hercules SM, Aarts CW, Dvorkin-Gheva A, Bramson JL, Hassell JA, Daniel JM.

Cell Death Dis. 2017 Mar 23;8(3):e2689. doi: 10.1038/cddis.2017.92.

10.

Tumor-targeting domains for chimeric antigen receptor T cells.

Bezverbnaya K, Mathews A, Sidhu J, Helsen CW, Bramson JL.

Immunotherapy. 2017 Jan;9(1):33-46. doi: 10.2217/imt-2016-0103. Review.

PMID:
28000526
11.

Immunogenicity of Varicella Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents.

Lelic A, Verschoor CP, Lau VW, Parsons R, Evelegh C, Bowdish DM, Bramson JL, Loeb MB.

J Infect Dis. 2016 Dec 15;214(12):1905-1910. Epub 2016 Oct 5.

PMID:
27707807
12.

Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.

Hammill JA, Afsahi A, Bramson JL, Helsen CW.

Methods Mol Biol. 2016;1458:137-57. doi: 10.1007/978-1-4939-3801-8_11.

PMID:
27581020
13.

Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, de Souza CT, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC.

PLoS One. 2016 Jul 18;11(7):e0159471. doi: 10.1371/journal.pone.0159471. eCollection 2016.

14.

Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, Tanese de Souza C, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC.

PLoS One. 2016 May 19;11(5):e0155947. doi: 10.1371/journal.pone.0155947. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0159471.

15.

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2016 Jun 1;196(11):4587-95. doi: 10.4049/jimmunol.1600106. Epub 2016 Apr 27.

16.

Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors.

Hammill JA, VanSeggelen H, Helsen CW, Denisova GF, Evelegh C, Tantalo DG, Bassett JD, Bramson JL.

J Immunother Cancer. 2015 Dec 15;3:55. doi: 10.1186/s40425-015-0099-4. eCollection 2015.

17.

An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation.

Verschoor CP, Lelic A, Bramson JL, Bowdish DM.

Front Immunol. 2015 Jul 27;6:380. doi: 10.3389/fimmu.2015.00380. eCollection 2015. Review.

18.

T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.

VanSeggelen H, Hammill JA, Dvorkin-Gheva A, Tantalo DG, Kwiecien JM, Denisova GF, Rabinovich B, Wan Y, Bramson JL.

Mol Ther. 2015 Oct;23(10):1600-10. doi: 10.1038/mt.2015.119. Epub 2015 Jun 30.

19.

Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity.

Karimi K, Karimi Y, Chan J, Boudreau JE, Basset J, Chew MV, Reid S, Bramson JL, Wan Y, Ashkar AA.

Innate Immun. 2015 Aug;21(6):626-34. doi: 10.1177/1753425915575078. Epub 2015 Mar 5.

PMID:
25749844
20.

Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly.

Verschoor CP, Loukov D, Naidoo A, Puchta A, Johnstone J, Millar J, Lelic A, Novakowski KE, Dorrington MG, Loeb M, Bramson JL, Bowdish DM.

Mol Immunol. 2015 May;65(1):148-56. doi: 10.1016/j.molimm.2015.01.015. Epub 2015 Feb 5.

PMID:
25660689
21.

Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.

VanSeggelen H, Tantalo DG, Afsahi A, Hammill JA, Bramson JL.

Mol Ther Oncolytics. 2015 Sep 9;2:15014. doi: 10.1038/mto.2015.14. eCollection 2015.

22.

Anti-pneumococcal deficits of monocyte-derived macrophages from the advanced-age, frail elderly and related impairments in PI3K-AKT signaling.

Verschoor CP, Johnstone J, Loeb M, Bramson JL, Bowdish DM.

Hum Immunol. 2014 Dec;75(12):1192-6. doi: 10.1016/j.humimm.2014.10.004. Epub 2014 Oct 13.

PMID:
25446401
23.

Circulating muramyl dipeptide is negatively associated with interleukin-10 in the frail elderly.

Verschoor CP, Naidoo A, Wallace JG, Johnstone J, Loeb M, Bramson JL, Bowdish DM.

Inflammation. 2015 Feb;38(1):272-7. doi: 10.1007/s10753-014-0030-z.

PMID:
25278013
24.

Alterations to the frequency and function of peripheral blood monocytes and associations with chronic disease in the advanced-age, frail elderly.

Verschoor CP, Johnstone J, Millar J, Parsons R, Lelic A, Loeb M, Bramson JL, Bowdish DM.

PLoS One. 2014 Aug 8;9(8):e104522. doi: 10.1371/journal.pone.0104522. eCollection 2014.

25.

Analysis of purified wild type and mutant adenovirus particles by SILAC based quantitative proteomics.

Alqahtani A, Heesom K, Bramson JL, Curiel D, Ugai H, Matthews DA.

J Gen Virol. 2014 Nov;95(Pt 11):2504-11. doi: 10.1099/vir.0.068221-0. Epub 2014 Aug 5.

26.

Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop.

Chabierski S, Barzon L, Papa A, Niedrig M, Bramson JL, Richner JM, Palù G, Diamond MS, Ulbert S.

BMC Infect Dis. 2014 May 9;14:246. doi: 10.1186/1471-2334-14-246.

27.

T helper cell IL-4 drives intestinal Th2 priming to oral peanut antigen, under the control of OX40L and independent of innate-like lymphocytes.

Chu DK, Mohammed-Ali Z, Jiménez-Saiz R, Walker TD, Goncharova S, Llop-Guevara A, Kong J, Gordon ME, Barra NG, Gillgrass AE, Van Seggelen H, Khan WI, Ashkar AA, Bramson JL, Humbles AA, Kolbeck R, Waserman S, Jordana M.

Mucosal Immunol. 2014 Nov;7(6):1395-404. doi: 10.1038/mi.2014.29. Epub 2014 Apr 30.

PMID:
24781052
28.

Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD.

Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25.

29.

Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.

McGray AJ, Hallett R, Bernard D, Swift SL, Zhu Z, Teoderascu F, Vanseggelen H, Hassell JA, Hurwitz AA, Wan Y, Bramson JL.

Mol Ther. 2014 Jan;22(1):206-18. doi: 10.1038/mt.2013.255. Epub 2013 Oct 23.

30.

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines.

Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y.

Oncoimmunology. 2013 Aug 1;2(8):e26013. Epub 2013 Aug 27.

31.

Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.

Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, Loeb M, Bramson JL, Bowdish DM.

J Leukoc Biol. 2013 Apr;93(4):633-7. doi: 10.1189/jlb.0912461. Epub 2013 Jan 22.

32.

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL, Wan Y.

Blood. 2013 Mar 28;121(13):2432-9. doi: 10.1182/blood-2012-06-438481. Epub 2013 Jan 16.

33.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y.

Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.

34.

The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age.

Lelic A, Verschoor CP, Ventresca M, Parsons R, Evelegh C, Bowdish D, Betts MR, Loeb MB, Bramson JL.

PLoS Pathog. 2012;8(12):e1003076. doi: 10.1371/journal.ppat.1003076. Epub 2012 Dec 13.

35.

A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.

Kulkarni YM, Chambers E, McGray AJ, Ware JS, Bramson JL, Klinke DJ 2nd.

Integr Biol (Camb). 2012 Aug;4(8):925-36. doi: 10.1039/c2ib20053h. Epub 2012 Jul 9.

36.

Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.

McGray AJ, Bernard D, Hallett R, Kelly R, Jha M, Gregory C, Bassett JD, Hassell JA, Pare G, Wan Y, Bramson JL.

Oncoimmunology. 2012 Jul 1;1(4):419-431.

37.

Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.

Bassett JD, Swift SL, VanSeggelen H, Hammill JA, McGray AJ, Evelegh C, Wan Y, Bramson JL.

Mol Ther. 2012 Apr;20(4):860-9. doi: 10.1038/mt.2011.281. Epub 2011 Dec 20.

38.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

39.

Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.

Bassett JD, Swift SL, Bramson JL.

Expert Rev Vaccines. 2011 Sep;10(9):1307-19. doi: 10.1586/erv.11.88. Review.

PMID:
21919620
40.

Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.

Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, Bramson JL, Medin JA.

Gene Ther. 2011 Oct;18(10):986-95. doi: 10.1038/gt.2011.53. Epub 2011 Apr 14.

PMID:
21490686
41.

Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions.

Eftimie R, Dushoff J, Bridle BW, Bramson JL, Earn DJ.

Bull Math Biol. 2011 Dec;73(12):2932-61. doi: 10.1007/s11538-011-9653-5. Epub 2011 Apr 8.

PMID:
21476110
42.

IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.

Boudreau JE, Stephenson KB, Wang F, Ashkar AA, Mossman KL, Lenz LL, Rosenthal KL, Bramson JL, Lichty BD, Wan Y.

Cancer Res. 2011 Apr 1;71(7):2497-506. doi: 10.1158/0008-5472.CAN-10-3025. Epub 2011 Feb 9.

43.

Surface phenotype and functionality of WNV specific T cells differ with age and disease severity.

Piazza P, McMurtrey CP, Lelic A, Cook RL, Hess R, Yablonsky E, Borowski L, Loeb MB, Bramson JL, Hildebrand WH, Rinaldo CR.

PLoS One. 2010 Dec 13;5(12):e15343. doi: 10.1371/journal.pone.0015343.

44.

Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production.

Wang AY, Crome SQ, Jenkins KM, Medin JA, Bramson JL, Levings MK.

Cancer Immunol Immunother. 2011 Mar;60(3):381-8. doi: 10.1007/s00262-010-0948-4. Epub 2010 Dec 14.

PMID:
21153637
45.

CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells.

Bassett JD, Yang TC, Bernard D, Millar JB, Swift SL, McGray AJ, VanSeggelen H, Boudreau JE, Finn JD, Parsons R, Evelegh C, Damjanovic D, Grinshtein N, Divangahi M, Zhang L, Xing Z, Wan Y, Bramson JL.

Blood. 2011 Jan 27;117(4):1146-55. doi: 10.1182/blood-2010-03-272336. Epub 2010 Nov 18.

46.

Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design.

Denisova GF, Denisov DA, Bramson JL.

Immunome Res. 2010 Nov 3;6 Suppl 2:S6. doi: 10.1186/1745-7580-6-S2-S6.

47.

Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.

Romieu-Mourez R, François M, Abate A, Boivin MN, Birman E, Bailey D, Bramson JL, Forner K, Young YK, Medin JA, Galipeau J.

Cancer Res. 2010 Oct 15;70(20):7742-7. doi: 10.1158/0008-5472.CAN-10-0296. Epub 2010 Oct 5.

48.

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.

Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98. Epub 2010 Jun 15.

49.

Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma.

Eftimie R, Bramson JL, Earn DJ.

J Theor Biol. 2010 Aug 7;265(3):467-80. doi: 10.1016/j.jtbi.2010.04.030. Epub 2010 May 5.

PMID:
20450922
50.

Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.

Bridle BW, Li J, Jiang S, Chang R, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2010 Apr 15;184(8):4269-75. doi: 10.4049/jimmunol.0901447. Epub 2010 Mar 17.

Supplemental Content

Loading ...
Support Center